Remove Books Remove Licensing Remove Pharmaceuticals
article thumbnail

A Closer Look At Our On-Site Compounding Pharmacies

Alta Sciences

Regulatory Excellence - Licenses for Schedule I through IV drug substances. BOOK A VISIT You may also be interested in the following webpages:​​​ Clinical Research Services Pharmaceutical CDMO and Contract Manufacturing Services DID YOU KNOW? Electronic security access to the pharmacy and video monitoring. -

article thumbnail

Twist Bioscience Announces Pricing of a $300 Million Upsized Public Offering of Common Stock

The Pharma Data

Twist may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products. are acting as joint book-running managers. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. Baird & Co. Incorporated is acting as lead manager.

DNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bridging science and technology: a biotech CEO’s perspective

Drug Target Review

who shared his thoughts on the challenges faced by biotech companies in drug discovery, highlighting the critical role of data and technology in overcoming inefficiencies in the pharmaceutical industry. He has published several papers and two books and has twelve issued patents. We interviewed Dr Neil Wilkie, CEO of Mironid Ltd.,

Science 52
article thumbnail

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

From 2010 to 2020, Dr Graham was VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., He is the author of five chapters and books and more than 140 peer-reviewed journal articles. Multiple IND’s, NDA/BLA filings and/or defense and multiple successful launches. Dr. Graham earned an M.D.,

Science 52
article thumbnail

BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million

The Pharma Data

is acting as the sole book-running manager for the offering. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization. Wainwright & Co.

article thumbnail

TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock – Dec 15, 2020

The Pharma Data

The Company anticipates using net proceeds from the offering to fund the continued development of ublituximab and umbralisib, the potential in-license, acquisition, development and commercialization of other pharmaceutical products, and for general corporate purposes. Morgan Securities LLC, Goldman Sachs & Co.

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in July and August 2024

Agency IQ

The following PDUFA dates were obtained from publicly available sources. and the E.C.

FDA 40